Join

Compare · CRWD vs ORPH

CRWD vs ORPH

Side-by-side comparison of CrowdStrike Holdings Inc. (CRWD) and Orphazyme A/S (ORPH): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CRWD and ORPH operate in Computer Software: Prepackaged Software (Technology), so they compete in similar markets.
  • CRWD is the larger of the two at $190.29B, about 1086.7x ORPH ($175.1M).
  • CRWD has hit the wire 44 times in the past 4 weeks while ORPH has been quiet.
  • CRWD has more recent analyst coverage (25 ratings vs 0 for ORPH).
MetricCRWDORPH
Company
CrowdStrike Holdings Inc.
Orphazyme A/S
Price
-
-
Market cap
$190.29B
$175.1M
1M return
-
-
1Y return
-
-
Industry
Computer Software: Prepackaged Software
Computer Software: Prepackaged Software
Exchange
NASDAQ
NASDAQ
IPO
2019
2020
News (4w)
44
0
Recent ratings
25
0
CRWD

CrowdStrike Holdings Inc.

CrowdStrike Holdings, Inc. provides cloud-delivered solutions for endpoint and cloud workload protection in the United States, Australia, Germany, India, Israel, Romania, and the United Kingdom. It offers 19 cloud modules on its Falcon platform through a software as a service subscription-based model that covers various security markets, such as corporate workload security, security and vulnerability management, managed security services, IT operations management, threat intelligence services, identity protection, and log management. The company primarily sells its platform and cloud modules through its direct sales team. CrowdStrike Holdings, Inc. was incorporated in 2011 and is headquartered in Sunnyvale, California.

ORPH

Orphazyme A/S

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

Latest CRWD

Latest ORPH